Stockscreener 앱 받기
10.94
2.93%
-0.33
시간 외 거래:
10.75
-0.19
-1.74%
Nurix Therapeutics Inc 주식(NRIX)의 최신 뉴스
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Sold by Price T Rowe Associates Inc. MD - MarketBeat
Needham & Company LLC Reaffirms "Buy" Rating for Nurix Therapeutics (NASDAQ:NRIX) - MarketBeat
Darwin Global Management Ltd. Invests $3.08 Million in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Boxer Capital Management LLC Takes $10.61 Million Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Invesco Ltd. Sells 361,360 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
JPMorgan Chase & Co. Has $582,000 Stock Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
RA Capital Management L.P. Buys New Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Lord Abbett & CO. LLC Boosts Stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
(NRIX) Trading Signals - news.stocktradersdaily.com
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Sold by T. Rowe Price Investment Management Inc. - MarketBeat
Nurix therapeutics’ chief scientific officer sells $38,841 in stock By Investing.com - Investing.com South Africa
Nurix therapeutics’ chief scientific officer sells $38,841 in stock - Investing.com
Nurix Therapeutics Executives Sell Shares for Tax Obligations - TradingView
Breaking Down Nurix Therapeutics: 7 Analysts Share Their Views - Benzinga
Nurix Therapeutics Presents Data at the AACR 2025 Annual Meeting Highlighting the Transformative Potential of Its Proprietary DEL-AI Platform Leveraging Machine Learning to Speed the Discovery of Novel Drugs - The Manila Times
Russell Investments Group Ltd. Grows Stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Stock Price Up 6.4%Here's Why - MarketBeat
Nurix Therapeutics reports breakthroughs in cancer drug research - Investing.com Australia
Jump Financial LLC Purchases New Stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Nurix Therapeutics Presents Positive Preclinical Data at the AAC - GuruFocus
Nurix Therapeutics Showcases Promising Preclinical Data for BTK, BRAF, and Aurora A Kinase Degraders at AACR 2025 Annual Meeting - Nasdaq
Nurix Therapeutics Presents Positive Preclinical Data at the AACR 2025 Annual Meeting from Multiple Orally Available, Brain Penetrant Degraders Against Three High Value Oncology Targets - The Manila Times
Revolutionary Brain-Penetrant Cancer Drugs Outperform Competitors: 10,000 Proteins Destroyed Per Hour - Stock Titan
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Receives $30.44 Average Price Target from Analysts - MarketBeat
Geode Capital Management LLC Acquires 137,087 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Shares Gap DownWhat's Next? - MarketBeat
Affinity Asset Advisors LLC Raises Stock Holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Wasatch Advisors LP Lowers Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Fmr LLC Grows Holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Sold by Trexquant Investment LP - MarketBeat
(NRIX) Technical Data - news.stocktradersdaily.com
Nurix advances IRAK4 degrader into Phase 1 trials with FDA nod - Investing.com Canada
Nurix Therapeutics: IRAK4 GS-6971 Isn't Only Protein Degrader With Big Potential - Seeking Alpha
Broker Revenue Forecasts For Nurix Therapeutics, Inc. (NASDAQ:NRIX) Are Surging Higher - simplywall.st
Nurix advances IRAK4 degrader into Phase 1 trials with FDA nod By Investing.com - Investing.com South Africa
Nurix Therapeutics (NRIX) Advances Experimental Drug Following FDA Clearance - GuruFocus
Nurix gets FDA clearance to initiate trial for its anti-inflammatory drug candidate - Seeking Alpha
FDA Clears IND for Nurix's (NRIX) IRAK4 Degrader, Phase 1 Trial Set for 2025 | NRIX Stock News - GuruFocus
Nurix Announces FDA Clearance of IND Application for GS-6791/NX-0479a Novel IRAK4 Degrader for Inflammatory Conditions - The Manila Times
0.39%
3.66%
자본화:
|
볼륨(24시간):